Melissa Palmer, MD, FAASLD
Biography
Melissa Palmer, MD has been a Hepatologist for over 35 years and is an experienced biotech/pharma executive. She is currently CEO of Liver Consulting LLC, consulting exclusively to biotech and pharmaceutical companies on hepatology-related issues such as: innovative trial designs for all liver diseases including metabolic dysfunction-associated steatotic hepatitis (MASH), PBC, Hepatitis B and D, primary sclerosing cholangitis (PSC), alcohol- associated liver disease and all aspects of liver disease drug development from pre-IND to NDA. Dr Palmer's specific expertise is in hepatotoxicity, DILI, hepatic adverse event adjudication and hepatic signal evaluation during clinical trials.
Sessions
2:00 PM
- 11:30 AM
Convention Center - Bluebird Ballroom 1C
Wait Wait...Don't DILI!
James Luyendyk, PhD | Moderator,
Jessica H Hartman, PhD | Presenter,
David E Kleiner, MD, PhD | Presenter,
Mitchell R McGill, PhD | Presenter,
Vincent Lo Re III, MD, MSCE | Presenter,
Lily Dara, MD | Panelist,
Dina Halegoua-DeMarzio, MD | Panelist,
Melissa Palmer, MD, FAASLD | Panelist,
Jonny Sexton, PhD | Panelist,
James Luyendyk, PhD | Chair
3:45 PM
- 12:45 PM
Convention Center - Summit 4, The Park @TLM, Hall D
The Weight of Hepatotoxicity: Liver Injury in the Age of Weight Loss Therapies
Melissa Palmer, MD, FAASLD | Presenter,
Dina Halegoua-DeMarzio, MD | Presenter,
Max A Garcia, BA/BS | Presenter,
Paul Hayashi, MD, MPH, FAASLD | Moderator,
Lily Dara, MD | Moderator,
Melissa Palmer, MD, FAASLD | Panelist,
Dina Halegoua-DeMarzio, MD | Panelist,
Max A Garcia, BA/BS | Panelist,
Jay H. Hoofnagle, MD, FAASLD | Panelist
